Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice (Q37954157)

25 August 2017

title

Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice (English)

1 reference

25 August 2017

main subject

autism spectrum disorder

0 references

0 references

1 reference

1 reference

Matthew Siegel

1

1 reference

25 August 2017

Amy A Beaulieu

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 August 2012

1 reference

Journal of Autism and Developmental Disorders

25 August 2017

published in

1 reference

25 August 2017

volume

42

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

1592-1605

1 reference

Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Naltrexone in autistic children: behavioral symptoms and attentional learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Naltrexone and communication skills in young children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Guanfacine in children with autism and/or intellectual disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Clonidine treatment of hyperactive and impulsive children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Identification and Evaluation of Children With Autism Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

An update on pharmacologic treatments for autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

A systematic review of medical treatments for children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Use of methylphenidate in the treatment of children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Development of the evaluative method for evaluating and determining evidence-based practices in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Placebo-controlled acute dosage naltrexone study in young autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10803-011-1399-2

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms

21 January 2018

1 reference

12 December 2020

Off-label second generation antipsychotics for impulse regulation disorders: a review.

1 reference

12 December 2020

Naltrexone in autistic children: a double-blind and placebo-controlled study

1 reference

12 December 2020

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

12 December 2020

10.1007/S10803-011-1399-2

Identifiers

DOI

1 reference

release_j6dokn2prfevvbk5kzhnghvr7i

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/j6dokn2prfevvbk5kzhnghvr7i

24 November 2022

mapped directly with Wikidata item

1 reference